Crohn^s disease and Asacol


Crohn^s Disease Symptoms and Causes

Crohn's disease causes inflammation of the digestive system. It is one of a group of diseases called inflammatory bowel disease. Crohn's can affect any area from the mouth to the anus. It often affects the lower part of the small intestine called the ileum.

The cause of Crohn's disease is unknown. It may be due to an abnormal reaction by the body's immune system. It also seems to run in some families. It most commonly starts between the ages of 13 and 30.

The most common symptoms are pain in the abdomen and diarrhea. Other symptoms include

  • Bleeding from the rectum
  • Weight loss
  • Fever

Your doctor will diagnose Crohn's disease with a physical exam, lab tests, imaging tests, and a colonoscopy.

Crohn's can cause complications, such as intestinal blockages, ulcers in the intestine, and problems getting enough nutrients. People with Crohn's can also have joint pain and skin problems. Children with the disease may have growth problems.

There is no cure for Crohn's. Treatment can help control symptoms, and may include medicines, nutrition supplements, and/or surgery. Some people have long periods of remission, when they are free of symptoms.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for crohn^s disease

crohn^s disease treatment research studies

Asacol clinical trials, surveys and public health registries

Find Drug Side Effect reports

Asacol Side Effects

Diarrhoea (42)
Colitis Ulcerative (32)
Abdominal Pain (27)
Arthralgia (26)
Injection Site Pain (25)
Fatigue (25)
Condition Aggravated (24)
Crohn's Disease (24)
Pyrexia (23)
Dyspnoea (17)
Nausea (17)
Dizziness (16)
Malaise (16)
Headache (15)
Dehydration (14)
Asthenia (14)
Pain (14)
Vomiting (14)
Rash (13)
Pancreatitis (12)
Chest Pain (12)
Cough (11)
Abdominal Pain Upper (11)
Back Pain (11)
Haematochezia (11)
Pain In Extremity (11)
Weight Decreased (10)
Hypoaesthesia (10)
Anaemia (10)
Alopecia (9)
Colitis (9)
Urticaria (9)
Incorrect Dose Administered (9)
Rectal Haemorrhage (9)
Pericarditis (8)
Pulmonary Embolism (8)
Hypersensitivity (8)
Diarrhoea Haemorrhagic (7)
Deep Vein Thrombosis (7)
Haemorrhage (7)
Erythema (7)
Insomnia (7)
Weight Increased (7)
Oedema Peripheral (7)
Myalgia (7)
Tremor (6)
Renal Failure (6)
Muscle Spasms (6)
Pancytopenia (6)
Pneumonia (6)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

I am taking 2 asacol three times a day and is very difficult sleep and my mouth is dry all the time.

After sterted with Asacol I had Pangreatitis

I am currently taking 12 400mg asacol pills at 4 pills, three times per day, as well as pentasa enemas twice a week, to induce remission of pancolitis. Before this flare up, I was taking four 400mg asacol pills per day. This year, in May 2011, I w

I am having anxiety or panic attacks, which I've never had before. I'm on the maintenance dose right now, 4 pills per day. I have been on asacol for five months, and all of a sudden, I am having these panicy side effects. Anyone else having them? Als

I have diabetes type 2 , does asacol have any side effects on me?

I was diagnoised with crohns and am taking 2400 mg per day for over a week with no real change in condition,I am in pain and depressed,will I improve soon?

I was just diagnosed with ulcertaive colitis (UC) back in July. I've been taking asacolHD (1 800mg pill 3 times a day) for 6 months now and had only my 2nd flare up begin a couple days after Christmas. We relocated in September and I had to get a n

I was started on asacol after a diagnosis of colitis. I began having diarreha, fatigue, muscle and joint pain, confusion, loss of appetite and shortness of breath.

I went into my doctors with severe stomach pain and was diagnosed prior to this visit with severe ulcerative colitis. Doctor said the pain was probably a flare up and put me on asacol EC 400mg 2 tablets twice a day. After close to

Severe nausea, not able to stand daily at times

A flu epidemic at a boarding school would be a concern for the Centers for Disease Control true or false?

Why do doctors keep the availabilty of the test for DPD deficiency a secret??? My sister is a doctor, infectious disease, at St Francis in Charleston, SC. Our father was treated by an oncologist well known to my sister, a 'colleague' you might s

I am having cramps, muscle pain, memory loss, I have been on Revlmid for about 1 year. Does anybody else my age have this disease, I am only 46 yr woman.

<b><span style=' padding: 0px; margin: 0px;'>Hi Can any1 tell me why this medicine (Betaserc) people use and if the disease is dangerous....plz tell me on urgent basis...any1 thnx</b>

<strong>I have very high blood pressure, was put on this drug approximately 5 weeks ago. I was on Coozar previous to this. I also take paracetamol x 1 bd, ceres x 1, venlafaxine x 1, omeprazole x 1, aspirin x 1, have Charcot Marie Tooth Disease

55 yo dx with osearthritis and degenative disc disease, prescribed Mobic 15 mg once a day on medication for past year with no problem.For the past 6weeks had gradual onset of facial and extremity edema , esophageal spasm and expir

After becoming very ill, suffering much pain, losing weight and having many sleepless nights i was finally diagnosed with hoshimotos disease, subsequently i have hypothyroidism. I am only talking 50 mg oroxine 3 times a week and 100 mg the other 2 d

As with any drug, you must weigh the benefits vs. the risks. Revlimid is an incredible drug, which controls my myeloplastic disease with deletion 5q

Can gestodene cause continous dizzyness or meniere's disease.

Centuximab has been diseastrous for me. My fingertips bleed and are infected as well as extremely painful to the touch. I have abdominal pains, constipation. What is worse, the CEA count has jumped and the disease has spread at an alarming rate.

Crohn^s Disease Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Dietary Supplement: Curcumin;   Drug: 5-aminosalicylic acid
Outcome Measures: The percentage of patients who achieve clinical remission compared between the two study arms.;   Time to response
2 Recruiting The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Condition: Irritable Bowel Syndrome
Interventions: Drug: Mesalamine;   Drug: Placebo
Outcome Measure: Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period
3 Recruiting Predicting Response to Standardized Pediatric Colitis Therapy
Condition: Ulcerative Colitis
Interventions: Drug: Mesalamine;   Drug: Prednisone;   Drug: Corticosteroids followed by mesalamine (Pentasa)
Outcome Measures: Corticosteroid free remission (SFR);   Corticosteroid free remission
4 Recruiting Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: MMX Mesalamine/Mesalazine
Outcome Measures: Clinical Response;   Maintenance of Clinical Response;   Clinical and Endoscopic Response;   Changes in Signs and Symptoms of Mild to Moderate Ulcerative Colitis;   Improvement in Mild to Moderate Ulcerative Colitis;   Remission
5 Recruiting Cimzia Versus Mesalamine for Crohn's Recurrence
Condition: Crohn's Disease
Interventions: Drug: Cimzia;   Drug: Mesalamine
Outcome Measures: Clinical recurrence rates of Crohn's disease;   Endoscopic recurrence of Crohn's disease
6 Recruiting Mesalazine Treatment in IBS (The MIBS Study)
Condition: Irritable Bowel Syndrome
Interventions: Drug: Mesalazine;   Drug: Placebo
Outcome Measures: Global Irritable Bowel Syndrome (IBS) symptoms;   Inflammatory mediators;   Effect on immune cells and cytokines in mucosal biopsies;   Levels of calprotectin in faeces;   Change in total IBS symptom severity score (IBS-SSS);   Individual symptom parameters in IBS symptom severity score (IBS-SSS) and the IBS diary;   Exploratory responder variables
7 Recruiting Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis
Condition: Mild to Moderate Ulcerative Colitis
Intervention: Drug: Mesalamine
Outcome Measures: Difference in mean PUCAI score between the groups.;   Treatment success defined as Complete response OR large partial response.
8 Recruiting Mesalazine Effects in Sporadic Colorectal Adenoma Patients
Condition: Sporadic Colorectal Adenoma
Interventions: Drug: Mesalazine;   Drug: Placebo
Outcome Measures: Apoptotic index;   Proliferation index;   Expression of β-catenin signaling pathway
9 Recruiting Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
Condition: Proctitis
Interventions: Drug: Budesonide 2 mg suppository;   Drug: Budesonide 4 mg suppository;   Drug: Mesalazine 1 g suppository;   Drug: Budesonide 2 mg suppository/Mesalazine 1 g suppository
Outcome Measures: Resolution of clinical symptoms;   Rate of clinical and endoscopic remission;   Rate of improvement;   Rate of patients with clinical remission;   Rate of patients with endoscopic remission
10 Recruiting TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
Condition: Active Ulcerative Colitis
Interventions: Drug: Mesalazine - TID 1000 mg;   Drug: Mesalazine - TID 2x 500 mg
Outcome Measures: Rate of clinical remission;   Number of stools per week;   Number of bloody stools per week;   Time to first resolution of clinical symptoms
11 Recruiting Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.
Conditions: Colorectal Cancer;   Diverticular Disease;   Colitis
Intervention: Drug: Mesalazine
Outcome Measures: Molecular analysis of gene expression levels of μ-protocadherin and other related proteins;   Evaluation of protein expression level of μ-protocadherin, Ki-67, Caspase-3 and Histone H2AXγ, evaluation of DNA oxidative damage and intra-mucosal concentration of 5-Acetylsalicylic acid
12 Recruiting Targeting Oxidative Stress in Chronic Beryllium Disease
Condition: Chronic Beryllium Disease
Interventions: Drug: Mesalamine;   Drug: Placebo
Outcome Measures: Beryllium lymphocyte proliferation responses (BeLPT);   Th1 cytokines;   Steady-state GSH levels;   HDAC2 levels;   Glucocorticoid receptors;   Lung function
13 Recruiting Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Ulcerative Colitis.
Condition: Ulcerative Colitis
Interventions: Drug: combination 5-aminosalicylic + hydrocortisone / prednisone;   Drug: IV hydrocortisone / PO prednisone
Outcome Measures: percentage of patients who respond to the treatment;   the percentage of patients in need of a rescue medication;   colectomy rate
14 Recruiting Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)
Conditions: Colitis, Ulcerative;   Inflammatory Bowel Diseases
Interventions: Drug: CGMP protein;   Drug: Maximal oral 5ASA
Outcome Measures: Fecal calprotectin reduction;   Clinical Activity Index;   Quality of life;   Endoscopic Mayo score;   Serial fecal calprotectin
15 Recruiting TP05 for the Treatment of Mild to Moderate Active UC
Condition: Acute Ulcerative Colitis
Interventions: Drug: TP05;   Drug: Asacol
Outcome Measures: Clinical and endoscopic remission;   safety;   proportion of patients in remission
16 Recruiting Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Condition: Crohn's Disease
Interventions: Drug: D9421-C capsule 3 mg;   Drug: Mesalazine tablets
Outcome Measures: Clinical efficacy change defined by a score of 180-400 on the Crohn's Disease Activity Index (CDAI) by assessment of the remission after 8-week treatment defined by a CDAI score of ≤150.;   Remission (ie, CDAI score of ≤150) after 2-week treatment;   Remission (ie, CDAI score of ≤150) after 4-week treatment;   Change in CDAI score;   Time to the first remission;   Clinical improvement defined by a remission (ie, CDAI score of ≤150) or a decrease in CDAI score of at least 100 from baseline;   Clinical improvement defined by a remission (ie, CDAI score of ≤150) or a decrease in CDAI score of at least 70 from baseline;   Change in disease specific health-related quality of life (HRQL) as defined by a score of 180-400 on the CDAI by assessment of the Inflammatory Bowel Disease Questionnaire (IBDQ) total score and all sub scores
17 Recruiting Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis
Condition: Lymphocytic Colitis
Interventions: Drug: Budesonide;   Drug: Mesalamine;   Other: Placebo
Outcome Measures: Rate of clinical remission;   Proportion of patients with histological improvement
18 Recruiting Evaluation of the Metabolome in Diverticular Disease
Condition: Simple Diverticular Disease
Interventions: Dietary Supplement: VSL#3;   Drug: Rifaximin;   Drug: Mesalazine;   Dietary Supplement: Psyllium
Outcome Measures: identify the metabolome of symptomatic uncomplicated Diverticular Disease (SUDD);   evaluate the symptomatology and metabolome;   evaluate the different metabolomes according to the treatment used;   Evaluate the effects of supplementation with VSL#3 on the metabolome of Diverticular Disease
19 Recruiting Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)
Condition: Ulcerative Colitis
Outcome Measures: Prevalence of "non-persistence" amongst patients prescribed topical mesalamine for UC;   Clinical outcome (remission / relapse) at 12 months grouped by persistence status;   Adherence phenotype details;   Quality-of-life score at 12 months
20 Recruiting Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
Conditions: Inflammatory Bowel Diseases;   Crohn's Disease;   Gastrointestinal Diseases;   Digestive System Diseases;   Intestinal Diseases
Intervention: Drug: Mesalazine, Tripterygium glycosides
Outcome Measures: Therapeutic effect measured by Crohn's Disease Activity Index (CDAI);   The Side effects of Tripterygium wilfordii (TW);   The change of Crohn's Disease Activity Index (CDAI );   The change of Simple Endoscopic Score for Crohn's Disease(SES-CD);   The change of the Inflammatory Bowel Disease Questionnaire (IBDQ)